Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Moderate Pain - Pipeline Review, H2 2013 - New Market Research Report


Print article Print article
2013-12-19 10:16:28 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Moderate Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- www.fastmr.com/prod/755146_moderate_pain_pipeline_review_h2_2013 ..

Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Moderate Pain.
* A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Moderate Pain.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Nektar Therapeutics, Esteve Group, Pain Therapeutics, Inc., Pfizer Inc., Menarini Group, Acura Pharmaceuticals, Inc., Elite Pharmaceuticals, Inc., Charleston Laboratories, Inc., Trevena, Inc., QRxPharma Limited, KemPharm, Inc., TheraQuest Biosciences, LLC

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Moderate Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Moderate Pain
Moderate Pain Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Moderate Pain Therapeutics - Products under Development by Companies
Companies Involved in Moderate Pain Therapeutics Development
Nektar Therapeutics
Esteve Group
Pain Therapeutics, Inc.
Pfizer Inc.
Menarini Group
Acura Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc.
Charleston Laboratories, Inc.
Trevena, Inc.
QRxPharma Limited
KemPharm, Inc.
TheraQuest Biosciences, LLC
Moderate Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PTI-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(oxycodone + naltrexone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxycodone ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTI-721 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(morphine + oxycodone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKTR-194 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levorphanol tartrate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydromorphone IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-58425 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HS-731 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(promethazine + hydrocodone + acetaminophen) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(oxycodone hydrochloride + naltrexone hydrochloride) Extended Release - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRV-734 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moderate Pain Therapeutics - Drug Profile Updates
Moderate Pain Therapeutics - Discontinued Products
Moderate Pain Therapeutics - Dormant Products
Moderate Pain - Product Development Milestones
Featured News & Press Releases
Sep 10, 2013: Relmada Therapeutics Announces Positive Results of LevoCap ER Pivotal Pharmacokinetic Study
Jun 26, 2013: QRxPharma Updates Moxduo NDA Review
May 17, 2012: Janssen Presents Phase III Study Results Of NUCYNTA ER Extended-Release Tablets At 31st Annual Scientific Meeting Of American Pain Society
Appendix
Methodology

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755146&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com